Dividend plan boosts Quest Diagnostics (NYSE: DGX) director stake

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Quest Diagnostics director Robert B. Carter reported a small acquisition of company stock through a dividend reinvestment plan. On April 20, 2026, he acquired 7 shares of common stock at $194.699 per share, bringing his direct holdings to 2,711 shares.

The shares were acquired automatically under a broker-administered dividend reinvestment plan and are eligible for deferred reporting on Form 5 under Rule 16a-6. Carter chose to report this routine transaction early on Form 4.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider CARTER ROBERT B

Role null

Type	Security	Shares	Price	Value
L	Common Stock	7	$194.699	$1K

Holdings After Transaction: Common Stock — 2,711 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Shares acquired: 7 shares Acquisition price: $194.699 per share Shares held after transaction: 2,711 shares

3 metrics

Shares acquired 7 shares Common Stock acquired on April 20, 2026

Acquisition price $194.699 per share Price for shares acquired via dividend reinvestment plan

Shares held after transaction 2,711 shares Direct holdings following the April 20, 2026 acquisition

Key Terms

dividend reinvestment plan, Rule 16a-6, Form 5, Form 4, +1 more

5 terms

dividend reinvestment plan financial

"Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker"

A dividend reinvestment plan lets shareholders automatically use cash dividends to buy more shares of the same company instead of receiving the money. It matters to investors because it turns regular payouts into a steady way to grow ownership and take advantage of compound returns—like having your savings automatically buy additional slices of a pie over time—while often reducing transaction costs and smoothing purchase timing.

Rule 16a-6 regulatory

"eligible for deferred reporting on Form 5 under Rule 16a-6"

Form 5 regulatory

"eligible for deferred reporting on Form 5 under Rule 16a-6"

A Form 5 is an annual report filed with the U.S. securities regulator by company insiders—such as officers, directors and large shareholders—to disclose any equity transactions or holdings that were missed or deferred during the year. Think of it as an end-of-year ledger adjustment that shows final insider ownership and late-reported trades; investors use it to verify insider confidence, detect possible conflicts of interest, and spot unusual patterns in insiders’ buying or selling.

Form 4 regulatory

"The reporting person has chosen to report such transaction early on this Form 4."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

small acquisition financial

"transaction_action: "small acquisition""

Form 4 Insider Transactions: What Each Field Means →

04/24/2026 - 06:23 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CARTER ROBERT B

(Last)

(First)

(Middle)

500 PLAZA DRIVE

(Street)

SECAUCUS

NEW JERSEY

07094

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/20/2026		L	V	7⁽¹⁾	A	$194.699	2,711	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.

Remarks:

	Sean D. Mersten, Attorney-in-Fact for Robert B. Carter	04/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Quest Diagnostics (DGX) report for Robert B. Carter?

Robert B. Carter reported a small acquisition of Quest Diagnostics common stock. He obtained 7 shares on April 20, 2026 through a broker-administered dividend reinvestment plan, electing to disclose the transaction early on Form 4 instead of waiting to report it on Form 5.

How many Quest Diagnostics (DGX) shares does Robert B. Carter hold after this Form 4?

After the reported transaction, Robert B. Carter directly holds 2,711 shares of Quest Diagnostics common stock. This reflects the addition of 7 shares acquired on April 20, 2026 via a dividend reinvestment plan that automatically reinvested cash dividends into company stock.

At what price were the new Quest Diagnostics (DGX) shares acquired in this filing?

The 7 Quest Diagnostics shares were acquired at a price of $194.699 per share. This price comes from a dividend reinvestment plan, where cash dividends are automatically used to purchase additional stock, rather than from an open-market discretionary purchase.

What does the transaction code "L" mean in this Quest Diagnostics (DGX) Form 4?

The transaction code “L” in this Form 4 indicates a small acquisition under Rule 16a-6. In this case, it covers 7 shares of Quest Diagnostics common stock acquired automatically through a dividend reinvestment plan, a routine mechanism for reinvesting dividends into additional shares.

Why was this Quest Diagnostics (DGX) dividend reinvestment reported on Form 4 instead of Form 5?

The filing notes the shares were eligible for deferred reporting on Form 5 under Rule 16a-6. However, Robert B. Carter chose to report the 7-share dividend reinvestment transaction early on Form 4, providing more timely disclosure of his updated share holdings.